REGULATORY

PMDA Looks to New Pre-Application Meetings to Shed Review Time

November 14, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Pharmaceuticals and Medical Devices Agency (PMDA) launched a new free consultation service on review schedules for new drugs in October as part of its efforts to shorten the review time and increase the predictability of approval. In this service,…

To read the full story

PMDA Begins Accepting Applications for Regulatory Review Schedule Meetings
October 9, 2014
PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014

REGULATORY

Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…